✨Excess fat makes the liver act like it's under viral attack.✨
In a new publication in @jclinicalinvest , we describe how a maladaptive antiviral stress response causes liver injury in metabolic liver disease (MASH). 1/14
Congratulations to CVRTI Director Dr. Robin Shaw on receiving the Breakthrough of the Year award at the 2026 University of Utah Innovation Awards!
Dr. Shaw's research focuses on addressing defects inside heart muscle cells, with the goal of repairing the underlying causes of heart failure rather than simply compensating for them.
We are proud to celebrate this well-deserved recognition and his continued contributions to cardiovascular research!
Read more about the award: https://t.co/EtM5a3F2EG
@RobinShawCVRTI@UofUInternalMed@UtahHealth@UofUMedicine@UofUResearch@UUtah
#CardiovascularResearch #MedicalInnovation #UniversityOfUtah
1/. New publication alert! 🚨
Our lab’s multi-year collaborative work with the labs of @gsducker and @RutterLab just published in @Nature. Our work led to the discovery of a new pathway through which the heart can use lactate to generate energy.
https://t.co/tR36G80fJW
Excited to share my new preprint from the @RutterLab! What sets a cell’s metabolic state? Using MPC1 as a readout in a CRISPR screen, we found that β-catenin regulates metabolic state in liver cancer cells, driving a switch from carbohydrate to fat oxidation. 🧵
We are excited to share this new preprint from our amazing postdoc, @luisci22! Luis discovered that liver cancer cells with overactive beta-catenin switch their mitochondrial fuel usage from glucose to fatty acid oxidation—an unexpected rewiring that challenges conventional Warburg metabolism.
What if we could predict the course of the next pandemic before it happened? Tyler Starr, PhD, biochemist at University of Utah Health, studies viral evolution to do just that. Watch the full presentation: https://t.co/hCucpRM76W
Blocking EFHD1 protects against liver damage in #MASH models: https://t.co/7JNWot52Np
Dipayan Chaudhuri @ChaudhuriLab & team @UUtah identify EFHD1 as a protein in liver cells that triggers a maladaptive viral response during metabolic stress. In human organoid and mouse models, blocking EFHD1 blunted hepatocyte damage.
The loss of EFHD1 in mouse liver resulted in longer, spaghetti-like mitochondria, as seen in image (1/3). The featured electron micrograph (2/3) shows a liver cell mitochondria about to undergo fission, surrounded by an extensive network of ER contacting it.
#LiverDisease
Today, the MitoCarta Tree of Life Consortium (MitoTOL) is releasing high-accuracy mitochondrial proteomes across diverse eukaryotes to empower studies of physiology, evolution, and disease:
https://t.co/hRt6ZG4lQP
All data can be accessed at:
https://t.co/oPFODZBQ60
Today at the 2026 Bioscience Symposium: CVRTI investigator Dipayan Chaudhuri (@ChaudhuriLab) will present work newly published in the Journal of Clinical Investigation (JCI).
Dr. Chaudhuri will join researchers from across the University of Utah for an afternoon of scientific presentations and discussion.
Today, September 8
11:00 AM - 7:00 PM
Cleone Peterson Eccles Alumni House
@RobinShawCVRTI
#CardiovascularResearch #BioscienceResearch #UniversityOfUtah
✨Excess fat makes the liver act like it's under viral attack.✨
In a new publication in @jclinicalinvest , we describe how a maladaptive antiviral stress response causes liver injury in metabolic liver disease (MASH). 1/14
@ghotamis@jclinicalinvest Thank you @ghotamis ! This means a lot to us coming from you, as your findings with @gparlakgul and @apsarruda on contact site disruption and the separate work on PKR were foundational to our efforts, as we tried to assess what EFHD1 was doing!